| Name | Value |
|---|---|
| Revenues | 168.6M |
| Cost of Revenue | 38.9M |
| Gross Profit | 129.7M |
| Operating Expense | 269.2M |
| Operating I/L | -139.5M |
| Other Income/Expense | 0.7M |
| Interest Income | 5.5M |
| Pretax | -138.9M |
| Income Tax Expense | 4.6M |
| Net Income/Loss | -143.5M |
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions in the United States. The company's flagship products include EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used for targeted nerve treatment. Additionally, Pacira BioSciences develops proprietary multivesicular liposome drug delivery technology, encapsulating drugs without altering their molecular structure.